{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:23:04Z","timestamp":1794604984653,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ahjo.2026.100939","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:52:31Z","timestamp":1791330751000},"page":"100939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study"],"prefix":"10.1016","volume":"71","author":[{"given":"Ambresh Kumar","family":"Gautam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudesh","family":"Prajapathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshyaya","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahid","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravesh","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2026.100939_bb0005","unstructured":"Cardiovascular diseases 2025. Accessed December 9, 2025 https:\/\/www.who.int\/health-topics\/cardiovascular-diseases."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0010","doi-asserted-by":"crossref","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Cesare","year":"2024","journal-title":"Glob. Heart"},{"key":"10.1016\/j.ahjo.2026.100939_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2023.100156","article-title":"The burgeoning cardiovascular disease epidemic in Indians \u2013 perspectives on contextual factors and potential solutions","volume":"12","author":"Kalra","year":"2023","journal-title":"The Lancet Regional Health - Southeast Asia."},{"issue":"8","key":"10.1016\/j.ahjo.2026.100939_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcdd12080300","article-title":"Intensive lipid-lowering therapy following acute coronary syndrome: the earlier the better","volume":"12","author":"Pradhan","year":"2025","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12055-023-01652-y","article-title":"Does high dose statin pretreatment affect global strains in patients undergoing valve replacement","volume":"40","author":"Prajapathi","year":"2024","journal-title":"Indian J. Thorac. Cardiovasc. Surg."},{"issue":"32","key":"10.1016\/j.ahjo.2026.100939_bb0030","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"8934","key":"10.1016\/j.ahjo.2026.100939_bb0045","first-page":"1383","volume":"344","year":"1994","journal-title":"Lancet"},{"issue":"9326","key":"10.1016\/j.ahjo.2026.100939_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.ahjo.2026.100939_bb0055","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahjo.2026.100939_bb0060","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100939_bb0065","article-title":"A study of extended lipid profile in patients with acute coronary syndrome: focus on Lipoprotein(a) and PCSK9","volume":"28","author":"Kumar","year":"2026","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"issue":"15","key":"10.1016\/j.ahjo.2026.100939_bb0070","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10106","key":"10.1016\/j.ahjo.2026.100939_bb0080","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahjo.2026.100939_bb0085","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"38","key":"10.1016\/j.ahjo.2026.100939_bb0090","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100939_bb0095","article-title":"Looking beyond LDL-cholesterol - a study on extended lipid profile in Indian patients with acute coronary syndrome","author":"Kumar","year":"2019","journal-title":"JCDR"},{"issue":"6","key":"10.1016\/j.ahjo.2026.100939_bb0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab."},{"issue":"22","key":"10.1016\/j.ahjo.2026.100939_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11226846","article-title":"Lipid profile and small dense low-density lipoprotein in acute coronary syndrome patients: relationships to demographic, clinical, angiographic, and therapeutic variables","volume":"11","author":"Pradhan","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jama.297.3.286","article-title":"Risk factors for early myocardial infarction in South Asians compared with individuals in other countries","volume":"297","author":"Joshi","year":"2007","journal-title":"JAMA"},{"issue":"11[Special]","key":"10.1016\/j.ahjo.2026.100939_bb0115","first-page":"8","article-title":"Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2020: Part III","volume":"68","author":"Puri","year":"2020","journal-title":"J. Assoc. Physicians India"},{"issue":"11","key":"10.1016\/j.ahjo.2026.100939_bb0120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100939_bb0125","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0130","first-page":"30","article-title":"Real-world efficacy of current lipid-lowering strategies in patients with acute coronary syndrome. Time to change the paradigm for treatment","volume":"24","author":"Zuin","year":"2023","journal-title":"G Ital Cardiol (Rome)."},{"key":"10.1016\/j.ahjo.2026.100939_bb0135","article-title":"Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- a retrospective real-world study LDL-C control in ACS","volume":"19","author":"Jain","year":"2023","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0140","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV","volume":"18","author":"Puri","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"3, Supplement","key":"10.1016\/j.ahjo.2026.100939_bb0145","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.jacl.2025.04.017","article-title":"Early triple lipid-lowering therapy in acute coronary syndrome: results from the multicentric LAI-REACT study","volume":"19","author":"Puri","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"3 suppl","key":"10.1016\/j.ahjo.2026.100939_bb0150","first-page":"7","article-title":"Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1","volume":"64","author":"Iyengar","year":"2016","journal-title":"J. Assoc. Physicians India"},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jacl.2022.03.008","article-title":"Evidence for intensive LDL-C lowering for acute coronary syndrome: recommendations from the Lipid Association of India","volume":"16","author":"Puri","year":"2022","journal-title":"J. Clin. Lipidol."},{"issue":"42","key":"10.1016\/j.ahjo.2026.100939_bb0160","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.59556\/japi.74.1444","article-title":"Early LDL-C lowering efficacy of high-intensity atorvastatin and ezetimibe combination compared with high-intensity atorvastatin alone in acute coronary syndrome: the LAI EARLY ACS study","volume":"74","author":"Mehta","year":"2026","journal-title":"J. Assoc. Physicians India"},{"issue":"15","key":"10.1016\/j.ahjo.2026.100939_bb0170","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0175","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.ahjo.2026.100939_bb0180","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"14","key":"10.1016\/j.ahjo.2026.100939_bb0190","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ahjo.2026.100939_bb0195","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ahjo.2026.100939_bb0200","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ahjo.2026.100939_bb0205","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2026.100939_bb0210","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ihj.2014.03.005","article-title":"Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study","volume":"66","author":"Guptha","year":"2014","journal-title":"Indian Heart J."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100939_bb0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/2230-8210.176362","article-title":"Gender differences in 7 years trends in cholesterol lipoproteins and lipids in India: insights from a hospital database","volume":"20","author":"Gupta","year":"2016","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103183","article-title":"The relevance of remnant cholesterol as a guide for lipid management in Indian subjects undergoing coronary revascularization","volume":"19","author":"Bansal","year":"2025","journal-title":"Diabetes Metab. Syndr."},{"issue":"2","key":"10.1016\/j.ahjo.2026.100939_bb0225","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ihj.2025.02.009","article-title":"Adherence to pharmacotherapy for secondary prevention of coronary heart disease: a registry-based prospective study","volume":"77","author":"Bana","year":"2025","journal-title":"Indian Heart J."},{"issue":"5","key":"10.1016\/j.ahjo.2026.100939_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2026.104543","article-title":"Low density lipoprotein target achivement in very high and extreme cardiovascular risk patients during a cardiac rehabilitation program","volume":"36","author":"Maloberti","year":"2026","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"15","key":"10.1016\/j.ahjo.2026.100939_bb0235","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100939_bb0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of Inclisiran: a single-country, multicenter, observational study (CHOLINET registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ahjo.2026.100939_bb0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jacl.2025.11.010","article-title":"From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: a Monte Carlo simulation within the ITACARE-P registry","volume":"20","author":"Faggiano","year":"2026","journal-title":"J. Clin. Lipidol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:01:54Z","timestamp":1794603714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S2666602226002284"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100939","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100939"}}